Share on LinkedInShare on LinkedIn

ARTICLE · 02 JULY 2020

FDA Issues New Guidance To Developers Of COVID-19 Vaccines

On June 30, 2020, the U.S. Food and Drug Administration (FDA) released new guidance to provide recommendations for sponsors to facilitate development of SARS-CoV-2 vaccines to prevent COVID-19.

United StatesCoronavirus (COVID-19)

On June 30, 2020, the U.S. Food and Drug Administration (FDA) released new guidance to provide recommendations for sponsors to facilitate development of SARS-CoV-2 vaccines to prevent COVID-19. The guidance highlights key requirements for conducting clinical trials under Investigational New Drug applications (IND), for chemistry, manufacturing, and controls (CMC) requirements in manufacturing, nonclinical and clinical data needs, as well as post-market safety monitoring.1  Like other COVID-19 guidance documents, the FDA is implementing the guidance without public comment.

FDA notes that "[t]here are many COVID-19 vaccines currently in development," and the Biotechnology Industry Organization (BIO) COVID-19 dashboard notes 161 vaccine candidates under development worldwide as of June 21, 2020.2  On June 30, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NAID), National Institutes of Health (NIH), confirmed in Senate

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from